Paroxysmal atrial fibrillation ablation with a novel temperature-controlled CF-sensing catheter: Q-FFICIENCY clinical and healthcare utilization benefits.
QDOT MICRO
QMODE+
healthcare utilization
quality of life
temperature-controlled ablation
very high-power short-duration
Journal
Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
15
09
2023
received:
30
06
2023
accepted:
22
09
2023
medline:
11
12
2023
pubmed:
23
10
2023
entrez:
23
10
2023
Statut:
ppublish
Résumé
The prospective, nonrandomized, multicenter Q-FFICIENCY study demonstrated the safety and 12-month efficacy of paroxysmal atrial fibrillation (AF) ablation with the novel QDOT MICRO temperature-controlled, contact force-sensing, radiofrequency (RF) catheter. Participants underwent pulmonary vein isolation with very high-power short-duration (vHPSD) mode (90 W, ≤4 s) alone or combined with conventional-power temperature-controlled (CPTC) mode (25-50 W). This study aimed to assess quality-of-life (QOL) and healthcare utilization (HCU) benefits experienced by Q-FFICIENCY study participants. Besides evaluating procedural efficiency, QOL and HCU were assessed through 12 months postablation via Atrial Fibrillation Effect on Quality-of-Life Tool (AFEQT) score, antiarrhythmic drug (AAD) use, and incidence of cardioversion and cardiovascular hospitalization. Of 191 participants enrolled, 166 were ablated with the new catheter. Compared to baseline, statistically significant, clinically meaningful improvements in composite and subcategories of AFEQT scores were observed at 3 months and sustained through 12 months (12-month increase, 29.3-44.2 points). Class I/III AAD use decreased from 97.6% (162/166) at baseline to 19.6% (31/158) during Months 6-12, representing a significant 79.9% reduction. The cardioversion rate significantly declined by 93.9% from 31.3% (12 months preablation) to 1.9% (evaluation period). One-year Kaplan-Meier estimates of freedom from all-cause and cardiovascular hospitalization were 80.9% (95% confidence interval [CI], 74.8%-86.9%) and 88.8% (95% CI, 84.0%-93.7%), respectively. Paroxysmal AF ablation with the novel temperature-controlled RF catheter in vHPSD mode, alone or with CPTC mode, led to clinically meaningful improvement in QOL and significant reduction in AAD use, cardioversion, and cardiovascular hospitalization.
Substances chimiques
Anti-Arrhythmia Agents
0
Types de publication
Controlled Clinical Trial
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2493-2503Subventions
Organisme : Biosense Webster, Inc.
Informations de copyright
© 2023 The Authors. Journal of Cardiovascular Electrophysiology published by Wiley Periodicals LLC.
Références
Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017;14:e275-e444.
Ladwig KH, Goette A, Atasoy S, Johar H. Psychological aspects of atrial fibrillation: a systematic narrative review: impact on incidence, cognition, prognosis, and symptom perception. Curr Cardiol Rep. 2020;22:137.
Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association. Circulation. 2022;145:e153-e639.
Mark DB, Anstrom KJ, Sheng S, et al. CABANA Investigator Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321:1275-1285.
Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373-498.
Osorio J, Hussein AA, Delaughter MC, et al. Q-FFICIENCY Trial Investigators Very high-power short-duration, temperature-controlled radiofrequency ablation in paroxysmal atrial fibrillation. JACC Clin Electrophysiol. 2023;9:468-480.
Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112:1142-1147.
Reddy VY, Grimaldi M, De Potter T, et al. Pulmonary vein isolation with very high power, short duration, temperature-controlled lesions. JACC Clin Electrophysiol. 2019;5:778-786.
De Potter T, Grimaldi M, Jensen HK, et al. Temperature-controlled catheter ablation for paroxysmal atrial fibrillation: the QDOT-MICRO workflow study. J Atr Fibrillation. 2021;13:20200460.
Holmes DN, Piccini JP, Allen LA, et al. Defining clinically important difference in the atrial fibrillation effect on quality-of-life score. Circ Cardiovasc Qual Outcomes. 2019;12:e005358.
Gupta D, Vijgen J, Potter TD, et al. Quality of life and healthcare utilisation improvements after atrial fibrillation ablation. Heart. 2021;107:1296-1302.
Andrade JG, Macle L, Verma A, et al. Quality of life and health care utilization in the CIRCA-DOSE study. JACC Clin Electrophysiol. 2020;6:935-944.
Lafuente-Lafuente C, Valembois L, Bergmann JF, Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2015;(3):CD005049.
January CT, Wann LS, Alpert JS, et al. ACC/AHA Task Force Members 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130:e199-e267.
Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383:1305-1316.
Kuck KH, Lebedev DS, Mikhaylov EN, et al. Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST). EP Europace. 2020;23:362-369a.
Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes. 2011;4:313-320.
Tripathi B, Atti V, Kumar V, et al. Outcomes and resource utilization associated with readmissions after atrial fibrillation hospitalizations. J Am Heart Assoc. 2019;8:e013026.